IN THE CLAIMS:

1-3. (Canceled)

4. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of an Mts1 protein.

5. (Original) The isolated multimeric Mts1 protein complex of claim 4, having a Mw in the range of about 30 kD to about 200 kD.

6. (Currently amended) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts1 protein is a wild type Mts1 protein.

7. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of Mts1-del75.

8. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts1 protein is of a mammalian origin.

9. (Canceled)

10. (Original) A pharmaceutical composition comprising the isolated complex of claim 4, and a pharmaceutically acceptable carrier.

11. (Previously presented) The pharmaceutical composition of claim 10, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.

12. (Previously presented) The pharmaceutical composition of claim 10, further comprising a neurotropic factor.

13. (Original) The pharmaceutical composition of claim 12, wherein said neurotropic factor is selected from the group consisting of bFGF, aFGF, CNTF, NGF, BDNF, GDNF, NT3, NT4/5, IGF-1 and IGF-II.

14-25. (Canceled)

26. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein is a human Mts-1 protein.

27. (Previously presented) The isolated multimeric Mts1 protein complex of claim 26, wherein said human Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 1.

28. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4, wherein said Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 2.

29. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of human Mts1-del75.